Jane Holmes-Walker, also referred to as Deborah Jane Holmes-Walker, serves as Clinical Associate Professor at the University of Sydney within Sydney Medical School and as Senior Staff Specialist Endocrinologist at Westmead Hospital. She graduated from the University of Sydney with MBBS Honours in 1988. She completed her specialist training in Endocrinology at Westmead Hospital and The Middlesex Hospital in London, subsequently undertaking a PhD at Westmead Hospital focused on genetic causes of diabetes. Holding Fellowship of the Royal Australasian College of Physicians (FRACP), she has maintained clinical practice since 1996 and was employed as a staff specialist in the Department of Endocrinology at Westmead Hospital in 1998. Appointed Clinical Associate Professor at the University of Sydney in 2007, she coordinates all Endocrinology teaching at Westmead Clinical School, including the Stage 2 Endocrinology Block and Stage 3 Endocrinology Selective for medical students.

Dr Holmes-Walker's academic interests and research specializations encompass type 1 diabetes management, clinical islet cell transplantation programs, insulin pump therapy including continuous subcutaneous insulin infusion, models of care for young adults transitioning from pediatric to adult diabetes services, and the impact of digital technologies such as continuous glucose monitoring and hybrid closed-loop automated insulin delivery systems on glycemic outcomes, hypoglycemia, and quality of life. She has authored 56 publications, achieving 1,556 citations. Prominent publications include "Benchmarking care outcomes for young adults with type 1 diabetes across Australia" (2021, Endocrinology, Diabetes & Metabolism); "Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys" (2022, Diabetes Technology & Therapeutics); "Nationally Subsidized Continuous Glucose Monitoring: A Cost-effectiveness Analysis" (2022, Value in Health); "Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network" (2022, Diabetes Care); "The Diabetes Management Experiences Questionnaire: Psychometric validation among adults with type 1 diabetes" (2023); and "Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes" (2024, Internal Medicine Journal). She has published widely on diabetes and osteoporosis topics.

Professional Email: jane.holmeswalker@sydney.edu.au